GUMBOHATCH®, YOUR SHIELD AGAINST EMERGENT IBDV THREATS
Infectious Bursal Disease virus (IBDV) is continuously evolving through antigenic drift, reassortment and recombination events, shaping its genetic diversity and pathogenicity.
- A major economic challenge for the poultry industry
- Emergent strains tend to be subclinical, complicating their detection
- All field IBDV strains retain the potential to induce immunosuppression
Next-generation immune-complex vaccine against Infectious Bursal Disease
Its unique formulation (strain HIPRA 1052 + egg origin IgY in excess) and stringent quality controls create the balance between efficacy and safety.
ON SUNNY DAYS
When Gumboro disease is under control or not yet detected, maintaining flock health and optimizing performance become the primary goals. GUMBOHATCH® ensures:
 |
NO IMMUNOSUPPRESSION: Prevented by the complete coating of all viral particles combined with unbond IgY, avoiding a too early replication GUMBOHATCH® protects chicks from the inflammatory lesions in the bursa without affecting productive parameters |
 |
REGARDLESS OF MDA LEVELS: Safe administration even in flocks with low maternal antibodies, giving peace of mind and simplified management |
ON RAINY DAYS
The presence of field strains indicates that current control strategies may not be fully effective. GUMBOHATCH® shields the bursa by blocking the replication of challenge viruses, unlike vaccines that relied only on humoral immunity.
 |
EARLY AND INDIVIDUAL PROTECTION: HIPRA 1052 strain features a high breakthrough titer, early bursal colonization and rapid seroconversion when MDA decline |
 |
THE SHIELD AGAINST EMERGENT STRAINS: by a powerful competitive exclusion |